TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06738758
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient used statins in early hospitalization, and then once a day for 12 months. Whether to adjust the lipid-lowering regimen during follow-up depends on physician's clinical decision and patient preference.
Study: NCT06737250
Drug: R2P -> RP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction(R2P) 21 days per cycles, 6 cycles~* NB02 : 60mg BID PO, Day 1-21~* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles~* Lenalidomide : 20mg QD PO, Day 1-14~Maintenance(RP) 21 days per cycles, until Progression~* NB02 : 60mg BID PO, Day 1-21~* Lenalidomide : 20mg QD PO, Day 1-14
Study: NCT04641819
Drug: Yangzheng Compound Mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of the treatment period, the investigator can decide whether to continue the medication based on the improvement of the subjects' sleep disturbance.~Medication during the follow-up period: subjects will enter the follow-up period after completing one course of Yangzheng Compound Mixture treatment or the end of the treatment period. Visits will be conducted once every 3 weeks, at least 2 times and no more than 4 times. For subjects in the experimental group, doctors can decide whether the patients should continue to receive Yangzheng Compound Mixture therapy in the follow-up period according to the improvement of sleep disorders, while for subjects in the control group, the patients can choose to start receiving Yangzheng Compound Mixture therapy in the follow-up period according to their own wishes and doctors' suggestions.
Study: NCT06739395
Drug: PD-1/PD-L1/PD-1&CTLA4 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refer to the respective instructions for use, and the dosage for combined use will be adaptively adjusted by the researcher.Essentially, for de novo combinations, we started patients at about 50% of the usual dose of each drug for two-drug combinations, and at about one-third of the dose of each drug for three-drug combinations. Patients then received escalating doses of drugs to tolerance, while being monitored closely by their treating physicians. Combinations of drugs with overlapping toxicities were avoided.
Study: NCT06741345
Drug: BIO 300 Oral Suspension
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of genistein nanoparticles for oral administration
Study: NCT06739213
Drug: SYHA1813
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose of SYHA1813 is 20mg QD
Study: NCT06739213
Drug: Investigator's Choice Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's Choice Treatment
Study: NCT06738576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implantation is carried out in the same way as the drug implantation
Study: NCT06735495
Drug: CD19&CD22 bispecific CAR-T cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will receive CD19\&CD22 bispecific CAR-T cells by intravenous infusion on day 0
Study: NCT06735144
Drug: FH-006
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous injection once every two weeks (Q2W), with a treatment period of 28 days
Study: NCT06735144
Drug: FH-006
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered once every 3 weeks (Q3W), with a treatment period of 21 days
Study: NCT06734572
Drug: 18F-FAPIBiotin
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose will be 148-296 MBq given intravenously.
Study: NCT05314517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered subcutaneously to match namilumab dosing
Study: NCT05432193
Drug: [Ga-68]-PNT6555
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[Ga-68\]-PNT6555 IV administered as imaging agent for PET/CT
Study: NCT05432193
Drug: [Lu-177]-PNT6555
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with FAP-avid disease as determined by the \[Ga-68\]-PNT6555 screening PET/CT will receive \[Lu-177\]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.
Study: NCT04988308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered subcutaneously.
Study: NCT05411965
Drug: BR3003C(R2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug 2 (R2): BR3003C of AstraZeneca Korea
Study: NCT06742996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT05329779
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is a 0.45% sodium chloride infusion.
Study: NCT06742736
Drug: BGF
Normalized name: ALCOHOL 620 mg in 1 g TOPICAL AEROSOL, FOAM [GBGF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
Study: NCT05235516
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: q3w iv
Study: NCT05373199
Drug: Euglycemic clamp with BC Combo THDB0207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
Study: NCT05373199
Drug: Euglycemic clamp with Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single dose of Lantus® during an euglycemic clamp procedure.
Study: NCT05373199
Drug: Euglycemic clamp with Humalog®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a single dose of Humalog® during an euglycemic clamp procedure.
Study: NCT06742892
Drug: HLX43 DOSE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06742892
Drug: HLX43 DOSE 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06742892
Drug: HLX43 DOSE 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 3; HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study: NCT06727396
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06716879
Drug: Donzakimig
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Donzakimig Pharmaceutical form: Subcutaneous solution
Study: NCT06716879
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Placebo Pharmaceutical form: Subcutaneous solution
Study: NCT04704063
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Tocovid Suprabio
Study: NCT06745063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 week treatment with 10mg placebo daily
Study: NCT06744686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT06743997
Drug: Test Drug (Eutropin Catridge, 48IU/Cartridge)
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liqid somatropin
Study: NCT06743997
Drug: Reference Drug (Eutropin, 4 IU/vial)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized somatropin
Study: NCT06743945
Drug: POLA-R-CHP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin
Study: NCT06743776
Drug: MN-166
Normalized name: Mn 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: MN-166 will be taken orally at a dose of 10 mg in the morning and 20 mg in the evening for the first 2 weeks, whereafter dose of 30 mg BID will be taken.
Study: NCT06744127
Drug: BR1015-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06744127
Drug: BR1015-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06745531
Drug: TS-172 20~60 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of TS-172 20\~60 mg/day
Study: NCT06745531
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of placebo
Study: NCT06740201
Drug: Cipepofol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjust plasma target-controlled concentration
Study: NCT06739044
Drug: HDG1901
Approvals — FDA: no, EMA: no, PMDA: no
Description: The starting dose is 0.25 mg once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly for 24 weeks.
Study: NCT06735131
Drug: chemotherapy regimen selected by the investigator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimens to be selected from: (1) Nab-paclitaxel (125 mg/m2 IV, days 1, 8, Q3W) (2) Gemcitabine (1000 mg/m² IV, days 1 and 8, Q3W) + carboplatin (AUC=2 IV, days 1 and 8, Q3W)
Study: NCT06735755
Drug: BEAM-301: Single dose of BEAM-301 administered by IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEAM-301 is designed to correct the G6PC1 c.247C\>T allele via an A:T-to-G:C base-pair substitution, resulting in restoration of G6Pase-α catalytic activity.
Study: NCT04185441
Drug: Tanzânia association
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanzânia association capsule
Study: NCT06581562
Drug: AB-101
Normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Study: NCT06581562
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects in all 4 indications will receive only one cycle of treatment.~Subjects with RA, PV or SLE will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2 and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 1000 mg on Day 1 and Day 15~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13 and Day 20~Subjects with GPA and MPA will receive one cycle of treatment as follows:~1. Fludarabine: 25 mg/m2 on Day 1, Day 2, and Day 3.~2. Cyclophosphamide: 1000 mg/m2 on Day 3~3. Rituximab: 375 mg/m2 on Day -2, Day 6, Day 13, and Day 20~4. AB-101: 1B NK cells (AlloNK) on Day 6, Day 13, and Day 20 The first dose of AB-101 should be administered at least 48 hours after the last infusion of the lymphodepletion regimen.
Study: NCT06741800
Drug: ACARIZAX®️
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACARIZAX®️：The recommended dose for adults (18-65 years) is one freeze-dried tablet (12 SQ-HDM) daily, placed under the tongue.
Study: NCT06742853
Drug: AZD0780
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0780 tablet will be administered orally.
Study: NCT06742853
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin tablet will be administered orally.
Study: NCT06742853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally.
Study: NCT06742957
Drug: VTAMA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream
Study: NCT06742957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream
Study: NCT06742138
Drug: QL2109
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL2109 will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs.
Study: NCT06742138
Drug: DARZALEX FASPRO®
Approvals — FDA: no, EMA: no, PMDA: no
Description: DARZALEX FASPRO® will be given 1800 mg subcutaneously at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Subjects will receive pre-infusion medications before infusions to mitigate potential IRRs
Study: NCT02985671
Drug: orphenadrine, acetaminophen, caffeine and diclofenac sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: orphenadrine 35mg, acetaminophen 325mg, caffeine 65mg and diclofenac sodium 50mg tablet
Study: NCT02985671
Drug: Diclofenac Sodium 50 MG
Normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Voltaren (diclofenac sodium 50mg) tablet
Study: NCT02985671
Drug: Placebo (for experimental drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet without active substances, manufactured to mimic experimental product tablet
Study: NCT02985671
Drug: Placebo (for Voltaren)
Normalized name: Voltarene
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablet without active substances, manufactured to mimic Voltaren 50mg tablet
Study: NCT06744374
Drug: BGF
Normalized name: ALCOHOL 620 mg in 1 g TOPICAL AEROSOL, FOAM [GBGF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/glycopyrrolate/formoterol fumarate
Study: NCT06744374
Drug: MITT
Normalized name: TRANSMITTER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-inhaler triple therapy
Study: NCT01970137
Drug: KPS-0373, High dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01970137
Drug: KPS-0373, Low dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02193217
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05836766
Drug: Y-6 sublingual tablets
Normalized name: Y
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Y-6 sublingual tablets for 28 days continuously.
Study: NCT05836766
Drug: Placebo tablets of Y-6 sublingual tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take Placebo tablets of Y-6 sublingual tablet for 28 days continuously.
Study: NCT05697016
Drug: The Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipients used for the sivelestat sodium
Study: NCT04589663
Drug: QMF149
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single inhaled dose of QMF149 (75/40 µg indacaterol acetate/MF fixed dose combination) administered via Concept 1 device on Day 6-9
Study: NCT04589663
Drug: Standard of Care (Soc)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma therapy: budesonide and salbutamol being the most frequently used (excluding MF and indacaterol acetate)
Study: NCT05955183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given orally to randomized participants as per the arm they are assigned.
Study: NCT06538077
Drug: Placebo for BCAA
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo comparator of 15 gm of skimmed milk powder will be used.
Study: NCT06736223
Drug: ITF2357
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITF2357 (INNM Givinostat hydrochloride Monohydrate), single dose
Study: NCT06719141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be administered with matching placebo orally or through G-tube/ PEG tube.
Study: NCT06361199
Drug: Proximod
Normalized name: TRACH ADAPT,PROXIMAL FLO SENS R#1050408
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose to establish the safety and PK profile in both healthy subjects and patients with rheumatoid arthritis
Study: NCT06361199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo controlled
Study: NCT06746480
Drug: Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratumoral injection only. The dosing date is Days 1 through 3.
Study: NCT06743243
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan OD tab. 50 mg placebo PO + Saline 20ml IV, one hour before general anesthesia.
Study: NCT06741566
Drug: intranasal saline group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 ml of saline 0.9 % twice daily for 2 days preoperatively at fixed time ( 9 am and 6 pm)
Study: NCT06741787
Drug: Patients desensitized by sublingual spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Oraltekzc®️(Canis familiari), Oraltek®️(Felis domesticus), Oraltek®️(Alternaria alternata), dosage form: sublingual spray.
Study: NCT05944926
Drug: Antidepressant medication (fluoxetine)
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
Study: NCT00002422
Drug: HE2000
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06748521
Drug: R-CHOP + X
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible participants will receive 1 cycle of R-CHOP therapy with genotyping and ctDNA testing at C1D14. Chemotherapy sensitive patients with C1D14 ctDNA negative or ctDNA LFC ≥ 2 will continue to receive R-CHOP therapy for up to 6 courses. Potentially resistant patients with C1D14 ctDNA positive and LFC \< 2 were stratified by DLBCL genotyping and treated with cycle 2-6 R-CHOP in combination with obutinib or decitabine or lenalidomide or Chidamide.
Study: NCT06751121
Drug: Clarithromycin 500mg
Normalized name: CLARITHROMYCIN 500MG TAB
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin 500 mg, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
Study: NCT06751121
Drug: DWC202301 30mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWC202301 30 mg placebo, capsule, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
Study: NCT06751121
Drug: DWP14012 40mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 40 mg placebo, tablet, orally, twice daily before a meal with the concomitant medications at the same time each day, if possible, during the treatment period (14 days)
Study: NCT05376644
Drug: 99mTc-ADAPT6
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single injection of 99mTc-ADAPT6, followed by gamma camera imaging 2 hours after injection.
Study: NCT06749795
Drug: LIV001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered for 8 weeks
Study: NCT06749795
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered for 8 weeks
Study: NCT05376644
Drug: 99mTc-DARPinG3
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection.
Study: NCT06745089
Drug: Ocular lubricant
Normalized name: ocular lubricant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular lubricants moisturize the ocular surface.
Study: NCT06744062
Drug: BR1015
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06744062
Drug: BR1015-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06744062
Drug: BR1015-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06015750
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be administered SC or orally weekly for 104 weeks.
Study: NCT06015750
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid will be given orally as long as methotrexate is being dosed.
Study: NCT06045507
Drug: MK-8527
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-8527 capsule
Study: NCT06045507
Drug: Placebo to MK-8527
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to MK-8527
Study: NCT06763705
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl will not be used in isolation but will be used in combination with either Midazolam or Propofol in Midazolam + Fentanyl group and Propofol + Fentanyl group, respectively.
Study: NCT06791460
Drug: Pegylated liposomal doxorubicin plus adebrelimab with mirabegron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle orally with daily mirabegron until intolerance or disease progression.
Study: NCT06791460
Drug: Pegylated liposomal doxorubicin plus adebrelimab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants receive pegylated liposomal doxorubicin at a dose of 20mg/m2 plus adebrelimab at a dose of 20 mg/kg via intravenous (IV) infusion plus on Day 1 of each 21-day cycle until intolerance or disease progression.
Study: NCT06787612
Drug: PLD
Normalized name: PLD1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered per the protocol
Study: NCT06739551
Drug: Methotrexate (drug)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral methotrexate 10 mg per week for 12 weeks
Study: NCT05710328
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive standard of care chemotherapy
Study: NCT06793995
Drug: LY03017
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose，administered orally for each period
Study: NCT06793995
Drug: LY03017
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose，administered orally
Study: NCT06793514
Drug: Placebo Drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo is also prepared in the form of probiotic supplement in the form of sachets with similar packaging by the bio-fermenting pharmaceutical company.
Study: NCT05291338
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: no optimal dosage of doxorubicin in TACE procedures (ranging from 30 to 75 mg/m2 up to a maximum of 150 mg/m2 ) according to tumor size
Study: NCT06786624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets
Study: NCT05822583
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (IV infusion of normal saline) + baseline IM